Carb-X Awards Day Zero Diagnostics $6.2m to Develop a New Test to Diagnose Deadly Superbug Infections Faster and Determine What Antibiotic Would Be Most Effective

(BOSTON)  – CARB-X is awarding Day Zero Diagnostics, based in Boston, up to US$6.2 million in non-dilutive funding to develop a diagnostic system that could diagnose bacterial infections more quickly – within hours rather than days – and show physicians which antibiotics are most likely to effectively treat the infection. The innovative technology combines whole-genome sequencing and machine learning to identify the species of a pathogen and its drug-resistance profile without the need for culture, providing physicians with vital information to speed the appropriate treatment of serious drug-resistant bacterial infections in hours rather than days.

Read more